Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy-Reference-Cited by-同舟云学术

Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy

Published:1997-10 Issue:9 Volume:20 Page:547-551
ISSN:0391-4097
Container-title:Journal of Endocrinological Investigation
language:en
Short-container-title:J Endocrinol Invest

Author:

Ciccarelli E.,Grottoli S.,Razzore P.,Gaia D.,Bertagna A.,Cirillo S.,Cammarota T.,Camanni M.,Camanni Franco

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/BF03348017.pdf

Reference18 articles.

1. Pontiroli A.E., Viberti G.C., Mangili R., Cammelli L., Dubini A. Selective and extremely long inhibition of PRL release in man by 1-ethyl 3 (3′ Dimethylamino propyl) urea-diphosphate (FCE 21336). Br. J. Clin. Pharmacol. 23: 433, 1987.

2. Melis G.B., Gambacciani M., Paoletti A.M., Beneventi F., Mais V., Baroldi P., Fioretti P. Dose-related prolactin inhibitory effects of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal and hyperprolactinemic women. J. Clin. Endocrinol. Metab. 65: 541, 1987.

3. Ferrari C., Barbieri C., Caldara R., Mucci M., Codecasa F., Paracchi A., Romano C., Boghen M., Dubini A. Long lasting PRL-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 63: 941, 1986.

4. Ciccarelli E., Giusti M., Miola C., Potenzoni F., Sghedoni D., Camanni F., Giordano G. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J. Clin. Endocrinol. Metab. 69: 725, 1989.

5. Ferrari C., Mattei A., Melis G.B., Paracchi A., Muratori M., Faglia G., Sghedoni D., Crosignani P.G. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J. Clin. Endocrinol. Metab. 68: 1201, 1989.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dopamine agonists for the treatment of pituitary tumours: From ergot extracts to next generation therapies;British Journal of Clinical Pharmacology;2023-01-30

2. The elusive role of prolactin in the sociality of the naked mole-rat;Hormones and Behavior;2022-07

3. Treatment of hyperprolactinemia: A single-institute experience;Journal of the Chinese Medical Association;2021-07-09

4. Prolactinoma through the female life cycle;Endocrine;2017-11-24

5. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy;Gynecological Endocrinology;2016-12-02